Cimeio Therapeutics
Basel
About Cimeio Therapeutics
Cimeio Therapeutics develops curative treatments for genetic diseases, hematologic malignancies, and severe autoimmune disorders. The technology platform developed by Cimeio is based on the design and expression of modified variants of naturally occurring cell surface proteins in HSCs. The SCIP platform could allow more patients facing debilitating and fatal diseases to receive a life-saving HSC transplant. Its mission is to significantly improve the eligibility and outcomes of hematopoietic stem cell transplants and adoptive cell therapy.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $50.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Apr 2022)
- Website: cimeio.com
- Phone: +41 61 577 2316
Industries & Categories
Biopharma, Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/cimeio-therapeutics-119143 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.